A Phase 2 interventional study of Infliximab and Methotrexate in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Terminated at 53 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-06.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 118th largest by enrollment of the 141 interventional ones that give a count, is one of 22 that started in 2009, is one of 20 in phase 2, and was the 54th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Brazil, Poland
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Belgium and 9 more countries
Ages 18+
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
219 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 22 · Phase 3 85 · Phase 4 28
First in 2001; this study’s year is marked. 22 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 132 across the 141 interventional studies, 182 across the 78 observational. Of the 214 that completed or were terminated, 139 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
1 of the studies in Arthritis, Rheumatoid by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
Add it to your calendar (.ics) → With an account.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase II, randomized, active-controlled, double-blind, double-dummy, parallel-group, multicenter study in the United States enrolling patients with active RA. The study will enroll approximately 290 patients at approximately 130 sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received two intravenous (IV) infusions of 200 mg ocrelizumab administered on Day 1 and Day 15 and placebo IV infliximab infusions administered on Day 1, Day 15, Week 6, and Week 14. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
Drug: Methotrexate · Drug: Methylprednisolone · Drug: Ocrelizumab · Drug: Placebo
Participants received four IV infusions of 5 mg/kg infliximab administered on Day 1, Day 15, Week 6, and Week 14 and placebo ocrelizumab infusions administered on Day 1 and Day 15. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
Drug: Infliximab · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Placebo
Intravenous repeating dose
Oral or parenteral repeating dose
Intravenous repeating dose
Intravenous repeating dose
Intravenous repeating dose
Change From Baseline in DAS28(ESR) at Week 20
Time frame: Week 20
Percentage of Participants With Clinical Response of 20% According to ACR Criteria
Time frame: Baseline up to 30 months
Percentage of Participants With Clinical Response of 50% According to ACR Criteria
Time frame: Baseline up to 30 months
Percentage of Participants With Clinical Response of 70% According to ACR Criteria
Time frame: Baseline up to 30 months
European League Against Rheumatism (EULAR) Response Rates
Time frame: Baseline up to 30 months
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
Time frame: Baseline up to 30 months
Change in Fatigue Visual Analog Scale Score (VAS)
Time frame: Baseline up to 30 months
Percentage of Participants With Adverse Events (AEs)
Time frame: Baseline up to 30 months
| Milestone | Ocrelizumab 200mg | Infliximab 5mg/kg |
|---|---|---|
| Started | 15 | 13 |
| Completed | 6 | 4 |
| Not completed | 9 | 9 |
| Withdrew: Sponsor decision to terminate study | 3 | 7 |
| Withdrew: Other reasons outside sponsor decision | 6 | 2 |
| Milestone | Ocrelizumab 200mg | Infliximab 5mg/kg |
|---|---|---|
| Started | 15 | 13 |
| Completed | 13 | 10 |
| Not completed | 2 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Sponsor decision to terminate study | 1 | 1 |
| Withdrew: Other reasons outside sponsor decision | 1 | 1 |
| Milestone | Ocrelizumab 200mg | Infliximab 5mg/kg |
|---|---|---|
| Started | 9 | 4 |
| Completed | 0 | 0 |
| Not completed | 9 | 4 |
| Withdrew: Sponsor decision to terminate study | 9 | 4 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
| Percentage of Participants | Ocrelizumab 200mg | Infliximab 5mg/kg |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 78.9 | 76.9 |
Collected over Baseline up to 43 months. Non-serious events are listed at a 0.05% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ocrelizumab 200mg | 0/19 (0%) | 2/19 (10.5%) | 15/19 (78.9%) |
| Infliximab 5mg/kg | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| Event | Ocrelizumab 200mg | Infliximab 5mg/kg |
|---|---|---|
| INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASERespiratory, thoracic and mediastinal disorders | 1/19 | 0/13 |
| ENTERITISGastrointestinal disorders | 1/19 | 0/13 |
| GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 1/19 | 0/13 |
| RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 1/19 | 0/13 |
| HUMERUS FRACTUREMusculoskeletal and connective tissue disorders | 1/19 | 0/13 |
| Event | Ocrelizumab 200mg | Infliximab 5mg/kg |
|---|---|---|
| RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders | 0/19 | 3/13 |
| UPPER RESPIRATORY TRACT INFECTIOnInfections and infestations | 4/19 | 1/13 |
| SINUSITISInfections and infestations | 3/19 | 0/13 |
| RASHSkin and subcutaneous tissue disorders | 3/19 | 0/13 |
| NAUSEAGastrointestinal disorders | 2/19 | 2/13 |
| CHILLSGeneral disorders | 1/19 | 2/13 |
| HEADACHENervous system disorders | 0/19 | 2/13 |
| HERPES ZOSTERInfections and infestations | 2/19 | 0/13 |
| DIARRHOEAGastrointestinal disorders | 2/19 | 1/13 |
| CYSTITISInfections and infestations | 0/19 | 1/13 |
| Age, Continuous(Years) | Ocrelizumab 200mg | Infliximab 5mg/kg | Total |
|---|---|---|---|
| Mean | 53.5 ± 12.9 | 54.2 ± 15.2 | 53.83 ± 13.97 |
| Sex: Female, Male(Participants) | Ocrelizumab 200mg | Infliximab 5mg/kg | Total |
|---|---|---|---|
| Female | 6 | 10 | 16 |
| Male | 9 | 3 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Ocrelizumab 200mg | Infliximab 5mg/kg | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 14 | 12 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ocrelizumab 200mg | Infliximab 5mg/kg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 6 |
| White | 12 | 9 | 21 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
No publications or documents are linked to this record.
Ran from Mar 2009 to primary completion in Nov 2012, 44 months.
Results were first posted in Nov 2020, 7 years 11 months after primary completion. A results delay was requested in Jan 2014.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab